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Background: Colorectal liver metastases (CLM) occur frequently and postoperative intestinal infection is a common
complication. Our previous study showed that probiotics could decrease the rate of infectious complications after
colectomy for colorectal cancer. To determine the effects of the perioperative administration of probiotics on serum
zonulin levels which is a marker of intestinal permeability and the subsequent impact on postoperative infectious
complications in patients with CLM.
Methods: 150 patients with CLM were randomly divided into control group (n = 68) and probiotics group (n = 66).
Probiotics and placebo were given orally for 6 days preoperatively and 10 days postoperatively to control group
and probiotics group respectively. We used the local resection for metastatic tumor ,while for large tumor, the
segmental hepatectomy. Postoperative outcome were recorded. Furthermore, complications in patients with
normal intestinal barrier function and the relation with serum zonulin were analyzed to evaluate the impact on the
liver barrier dysfunction.
Results: The incidence of infectious complications in the probiotics group was lower than control group. Analysis
of CLM patients with normal postoperative intestinal barrier function paralleled with the serum zonulin level. And
probiotics could also reduce the concentration of serum zonulin (P = 0.004) and plasma endotoxin (P < 0.001).
Conclusion: Perioperative probiotics treatment could reduce the serum zonulin level, the rate of postoperative
septicemia and maintain the liver barrier in patients undergoing CLM surgery. we propose a new model about the
regulation of probiotics to liver barrier via clinical regulatory pathway. We recommend the preoperative oral intake
of probiotics combined with postoperative continued probiotics treatment in patients who undergo CLM surgery.
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The liver is a common site for metastatic disease [1].
Over 50% of the primary tumor are originated from the
gastrointestinal tract, especially colon and rectum [2].
Because morbidity and mortality of colorectal cancer
(CRC) increased year by year, CRC has been ranked as
the second cause of tumor death around the world [3]
and liver is the most common site of metastases of CRC
[4-6]. Resection of colorectal liver metastases (CLM) is
the best choice for the treatment of CRC with liver metas-
tasis [7], it is reported that simultaneous resection is as ef-
ficient as a delayed procedure for long-term survival [8].
With the development of advanced surgical tech-
niques, postoperative survival rate of CLM has been
considerably promoted [9]. However, the incidence of
postoperative infectious complications are becoming
more and more common [10,11]. These complications
may also lead to higher rates of recurrence and death
[12-15].
It is known to all that PRO play an important role in
the stability of the intestinal microbiological environment
[16,17]. In recent years, some randomized clinical trials
using PRO for to surgical patients for the protective
effects perioperatively [18-20] could regulate intestinal
microbial populations, lower intestinal permeability,
decrease the incidence of infection-related complica-
tions and overcome other problems, significantly.
Zonulin, the only known physiological modulator of
intercellular TJ described so far, is a protein which con-
stitutes tight junctions of the digestive tract and modu-
lates intestinal permeability [1,21]. Recently, zonulin was
found to be a reflection of the intestinal permeability
[22]. It is reported that elevated levels of plasma zonulin
in septic patients might serve as a mechanism for
increased intestinal permeability in sepsis and systemic
inflammatory response syndrome (SIRS) [23]. Another
study showed that zonulin both in vitro and in vivo
induced generation of complement C3a and C5a, sug-
gesting that zonulin facilitated the development of acute
lung injury and lung barrier by enhancing albumin leak
and complement activation as well as increased build up
of neutrophils and cytokines [24]. However, no study has
explored the link about zonulin, liver barrier and the
rates of complications after CLM surgery, the specific
role of PRO has not been elucidated yet.
Our previous study indicated that PRO could increase
transepithelial resistance (TER) and increase fecal bac-
terial variety, reduce transmucosal permeability of horse-
radish peroxidase, lactulose/mannitol ratio, bacterial
translocation rate, ileal-bile acid binding protein, positive
rate of blood bacterial DNA, blood enteropathogenic
bacteria [11]. Further study showed that PRO decreased
the serum zonulin concentration, the duration of post-
operative pyrexia, duration of antibiotic therapy and therate of postoperative infective complications in patients
underwent colectomy [1].
As liver barrier may have an impact on the incidence
of postoperative liver complications, we proposed the
hypothesis that pre- and postoperative PRO may reduce
liver permeability, decrease the rate of bacterial trans-
location (BT) and infectious complications after CLM
surgery. we aimed to investigate the effects of the peri-
operative administration of PRO on serum zonulin
levels, liver permeability and the subsequent impact on
postoperative liver complications in patients undergoing
CLM.
Methods
Inclusion and exclusion criteria
Inclusion criteria in our study included: 1) age between
25 and 75 years; 2) the diagnosis of CRC were confirmed
by biopsy and histological testing, liver metastases were
diagnosed by CT preoperatively and confirmed by post-
operative histological report; 3) patients underwent a
radical resection of primary colorectal tumors and liver
metastases; and 4) they had no other metastasis.
The exclusion criteria were as follows: 1) pregnant; 3)
lactose intolerance; 4) clinically significant immunodefi-
ciency; 5) gastrointestinal disorders (e.g., Crohn’s disease
or ulcerative colitis); 6) received antibiotics during the
10 days before surgery; 7) infection; 8) probiotic or ex-
cessive fiber intake within 2 weeks of surgery; 9)under-
went an emergency operation; 10) bowel preparation for
colonoscopy prior to surgery within 6 days; 11)under-
went a proctectomy with low rectal anastomosis or
surgery for a polypoid lesion; 12) the surgery was per-
formed laparoscopically; 13) received preoperative neoad-
juvant chemotherapy or radiotherapy; 14) had other
distant metastases except liver; 15) unresectable liver me-
tastases; and 16) severe liver function failure or other
organ failure.
Patients
150 patients with CLM were scheduled to undergo col-
ectomy at the Shanghai Sixth People’s Hospital, affiliated
to Shanghai JiaoTong University in Shanghai or the
Sixth Affiliated Hospital of Sun Yat-sen University in
Guangzhou, between April 2007 and July 2013. The pa-
tients were randomized prior to surgery to the placebo
control group (control) with perioperative oral feeding
placebo or the PRO therapy group (PRO) with PRO
treatment pre- and post-operatively. The study protocols
were reviewed and approved by the Human Research
Review Committee of the two hospitals and written in-
formed consent for participation were obtained from
each patient [1]. The requirement for informed consent
was waived by each of the institutional review boards
(IRBs) that approved the study (Human Research Review
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Yat-sen University).
All patients were assessed for eligibility, while 16 pa-
tients were excluded, for whom did not meet the inclu-
sion criteria (10 patients) or refused to participate (6
patients). 117 of the 134 patients completed the entire
study (Figure 1). There were no significant differences in
sex, age, BMI, time between the onset of symptoms and
hospital admission, no significant difference was found
in the preoperative serum levels of albumin, Hb, creatin-
ine, and operative time, intra-operative blood loss, intra-
operative transfusion, usage of supplemental albumin
postoperation, preoperative preparation time the num-
ber of patients treated with metronidazole, penicillin,
ceftriaxone, liver function (ALT and AST) (Table 1 for
intention-to-treat and Additional file 1: Table S1 for per-
protocol).
Study design, PRO treatment, and patient care
Randomization to two groups was accomplished using
double randomization principle (with the help of enve-
lopes and random variation row) constitution in our pa-
tient department of the Sixth Affiliated Hospital of Sun
Yat-sen University. Only a nurse knew the treatment as-
signment who was not directly involved in the trial and
could broke the treatment codes in the event of an
emergency.
Patients in the PRO group received encapsulated ad-
mixture of three PRO bacteria (Institute of Life
Science of Only, Shanghai Jiao Tong University,
Shanghai, China), composed of LP (CGMCC No.1258,
cell count ≥1011 cfu/g), LA-11 (cell count ≥7.0 ×
1010 cfu/g) and BL-88 (cell count ≥5.0 × 1010 cfu/g)Figure 1 Flow chart of the randomization procedure used to enroll pevery day. An acid-resistant coating was used to pre-
pare the capsules which wrapping the PRO a or pla-
cebo. Each patient in the PRO group received PRO
2 g/day, at a total daily dose of 2.6 × 1014 cfu. Patients
in the control group received daily encapsulated
maltodextrin. The appearance, smell and taste of the
two types of capsules showed no obvious difference.
The intervention period lasted 16 days, 6 days pre-
operatively and 10 days postoperatively. All the subjects
were interviewed by the study nurse, any reactions to
the product, medications taken and adverse events that
occurred were recorded.
During the study period, no parenteral or enteral nu-
tritional supplementation was given. All patients re-
ceived a regular diet preoperatively, and a low-residue
diet 1 day preoperatively. Mechanical bowel preparation
was given 1 day before the surgery, in which all patients
were given Soffodex, containing 2.4 g of monobasic so-
dium phosphate and 0.9 g of dibasic sodium phosphate.
Parenteral hydration was given on the morning of the
surgery via a central venous catheter. A catheter was
placed for gastric aspiration to reduce flow through the
colon anastomosis. 500 mg of metronidazole and 1 g of
ceftriaxone were given 1 h before induction and contin-
ued for 48 h after surgery. After the surgery, all patients
received regular parenteral hydration. Complications
were registered daily and patients were re-examined at
the outpatient clinic 1, 2, and 4 weeks after surgery.
Postoperative clinical observations
Detailed postoperative records were kept daily and infec-
tious complications were recorded for up to 30 days
after surgery. The diagnosis of bacterial infection wasatients in the study.
Table 1 Baseline of characteristics of the patients with colorectal liver metastases undergoing surgery at hospital
admission in the study (Intention-to-treat)
Index Control group (n = 68) PRO group (n = 66)
Sex (Male/Female) 35/33 35/31
Age (Year) 60.16 ± 16.20 65.62 ± 18.18
BMI (kg/m2) 23.06 ± 5.26 22.28 ± 3.66
Location of tumor
ascending colon 15 15
Transverse colon 6 5
Descending colon 12 16
Sigmoid colon 15 11
Rectum 20 19
Time between onset of symptoms and hospital admission (d) 50.28 ± 16.62 55.12 ± 18.26
Preoperative albumin (g/dL) 38.26 ± 8.56 36.98 ± 6.96
Preoperative Hb (g/L) 126.86 ± 32.06 116.22 ± 36.68
Creatinine (mg/dL) 1.26 ± 0.28 1.20 ± 0.62
Operative time (min) 186.28 ± 56.36 199.82 ± 55.98
Intra-operative blood loss (ml) 336.26 ± 182.68 352.56 ± 169.26
Transfusion during operation (ml) 308.12 ± 120.66 329.16 ± 130.58
Usage of supplemental albumin postoperation (g) 22.38 ± 16.36 28.12 ± 20.98
Preoperation prepared time (d) 6.12 ± 3.52 6.68 ± 2.98
Metronidazole (n) 68 66
Penicillin (n) 30 33
Ceftriaxone (n) 38 33
ALT (U/L) 35.68 ± 15.26 32.62 ± 18.86
AST (U/L) 29.68 ± 16.56 28.22 ± 18.86
BMI, body mass index; Hb, hemoglobin; ALT, alanine transarninase (normal value, 0–40 U/L); AST, aspartate aminotransferase (normal value, 0–40 U/L).
There were no significant differences about the characteristics between the two groups.
Quantitative data are expressed as mean ± standard deviation. Numerical data were compared by t test and nominal data by Pearson χ2 test or Fisher’s exact test
between groups.
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of complications were observed after surgery. The septi-
cemia incidence, liver function after 10 days postoperative,
the use of PRO, intra-abdominal drainage time and
infections-related complication were recorded. One of the
three doctors examine the patients (Liang Kang, Peng
Zhang, and Chao Li) to evaluate bowel sounds, abdominal
cramping, and distension on the postoperative days.
Our previous study [1] indicated that PRO lower the
intestinal permeability and the postoperative septicemia
rate. In this study, we further investigate the effects of
PRO on the liver barrier by comparing the postoperative
infection-related complications with normal intestinal
permeability at day 3 after surgery to eliminate the inter-
ference of intestinal barrier.
Measurement of serum zonulin concentration
The concentration of serum zonulin collected at 24 h
postoperatively were determined using an ELISA kit
[25]. Briefly, plastic microtiter plates (Costar, Cambridge,MA) were coated with rabbit zonulin cross-reacting Zot
derivative ΔG IgG antibodies (10 μg/ml in 0.1 mol/l so-
dium carbonate buffer, pH 9.0) [25]. After an overnight
incubation at 4°C, plates were washed four times in
TBS-T and blocked by incubation for 1 h at 37°C with
TBS-T. After four washes in TBS-T, five ΔG serial stan-
dards (50, 25, 12.5, 6.2, 3.1, and 0 ng/ml) and patient
sera samples (1:101 dilution in TBS-T) were added and
incubated overnight at 4°C. After four washes with Tris-
buffered saline 0.2% Tween 20 buffer, plates were incu-
bated with biotinylated anti-Zot IgG antibodies for 4 h
at 4°C. A color reaction was developed using a commer-
cial kit (ELISA amplification kit; Invitrogen). The ab-
sorbance at 495 nm was measured with a microplate
auto-reader (Molecular Devices Thermomax Microplate
Reader).
Intestinal permeability assay
Intestinal permeability was assessed using the L/M test
preoperatively (the morning of the surgery) and on the
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night fast, all subjects were given the oral test solution
containing 10 g of lactulose (Sigma-Aldrich, Tokyo,
Japan) and 5 g of mannitol (Sigma-Aldrich) in 60 ml of
physiological saline. For the next 6 h, the subjects were
rested and no food or water was allowed. Complete 6 h
urine collections were taken and a further 10-mL urine
sample was frozen at −20°C until analysis. Urinary lactu-
lose and mannitol concentrations were measured by
gas–liquid chromatography.
Measurement of plasma concentrations of endotoxin
Plasma samples used for endotoxin measurements were
stored in endotoxin-free glass tubes to prevent the loss
of endotoxin to plastic tubes walls. All materials used for
the assay were rendered endotoxin-free. Plasma endo-
toxin concentrations were measured by a commercially
available kit [Cambrex Limulus Amebocyte Lysate (LAL)
kit; Lonza Inc, Walkersville, MD] [26]. LPS from the
sample reacts enzymatically with a proenzyme in the
LAL reagent that leads to its activation and the produc-
tion of a colored peptide from the chromogenic sub-
strate reagent over a short incubation period that can be
read at 405–410 nm.
Microbiological investigations and PCR assay for bacterial
DNA fragment
Clinical samples comprising blood (40 mL), central lines
(tips), urine (20 mL), and sputum were collected at
06:00 [11]. Each clinical sample was taken approximately
72 h after the operation, and immediately sent to the
microbiological laboratory. The specimens were cultured
under aerobic condition, microaerophilic condition and
anaerobic condition respectively at 35-37°C for 24–48 h.
Anaerobic cultivation was performed in anaerobic cham-
ber. Sabouraud’s medium (bioMérieux, France) were used
in the Fungal cultures. The biochemical characteristics of
the cultured strains were investigated using the API and/
or ID tests (bioMérieux, France). The remaining 20 mL of
blood was collected in a sterile container containing
EDTA. To determine the sensitivity of the PCR detection,
serial dilutions of the spiked blood were tested until a
negative result. The sensitivity of the test was 10 organ-
isms/mL.
RNA extraction, cDNA synthesis, and real-time quantitative
PCR (qRT-PCR)
Our previous study indicated that the p38 mitogen-
activated protein kinase (MAPK) signaling pathway was
involved in the protective process of intestinal perme-
ability and intestinal barrier function [27]. Thus, we de-
termined the liver p38 MAPK gene expression using the
RT-PCR [25,27]. Briefly, total RNA was extracted from
the adjacent normal liver tissues of five patients withCLM using Trizol reagent (Invitrogen, Grand Island,
NY) to detect the expression level of p38 MAPK. For
each sample, 600 ng of mRNA was used in the reverse
transcription reaction (iScript kit from BioRad Labora-
tories, Hercules, CA, USA). Further analysis of the
mRNA levels of each group was performed by real time
PCR with a light-cycling system (LightCycler; Roche
Diagnostics GmbH, Mannheim, Germany). All values
were expressed as a fold increase or decrease compare
with the expression of actin. The sequences of the
primers were as follows: p38 MAPK, F: 5′-GAA-
GAGCCTGACCTACGAT-3′ and R: 5′-ACTGCCAAG-
GAGCATCTA-3′; β-actin, F: 5′-CTCCATCCTGGCC
TCGCTGT-3′ and R: 5′-GCTGTCACCTTCACCGTT
CC-3′.
Statistical analysis
A sample size calculation based on the prevalence of BT
demonstrated that approximately 120 patients would be
required in each group to demonstrate a reduction in
BT from 25% to 5% at the 5% significance level with a
power of 80% [1]. Results were analyzed using SPSS 13.0
version for Windows (SPSS, Chicago, Illinois, USA).
Quantitative data are expressed as mean ± standard devi-
ation. For postoperative clinical tests, numerical data
were compared by t-tests and nominal data were ana-
lyzed between groups with the Pearson χ2 test or Fisher’s
exact test. A P-value <0.05 was considered statistically
significant. Spearman’s correlation was used to assess
the relationship between zonulin level and outcome
using SPSS 13.0.
Results and discussion
PRO reduced postoperative intestinal infection related
complications and promoted rapid recovery
We first performed the comparison of overall postopera-
tive outcomes between PRO and control groups (Table 2
& Additional file 2: Table S2), which verified our previ-
ous study [1]. Among the 134 patients, no death case
was found, no patients got complications related leakage
of the anastomosis, fistulas, and abdominal hemorrhage,
no side effect of probiotic was reported in our study. Re-
sults indicated that the incidence of infectious complica-
tions in the PRO group was lower than the control
group, such as septicemia incidence (59% vs 88%, P =
0.008), urinary infection (2% vs 13%, P = 0.017), diarrhea
incidence (24% vs 46%, P = 0.012), then decrease the
duration of postoperative pyrexia (6.02 ± 1.68 vs 6.98 ±
2.22, P = 0.006), cumulative duration of antibiotic ther-
apy (6.22 ± 1.96 vs 7.56 ± 2.26, P < 0.001), postoperative
hospital stay (11.26 ± 2.52 vs 12.96 ± 3.06, P < 0.001), and
the overall hospital charge (52261.16 ± 12168.28 vs
58262.36 ± 10262.36, P = 0.002). For the liver function
indexes, both ALT and AST were significantly lowered
Table 2 Comparison of postoperative outcomes between probiotics and control (Intention-to-treat)
Outcomes Intention-to-treat
Control (n = 68) PRO (n = 66) P Value
Septicemia incidence (%) 88 (60/68) 59 (39/66) 0.008
ALT (U/L) 56.20 ± 18.16 36.28 ± 18.92 <0.001
AST (U/L) 45.62 ± 22.68 36.18 ± 21.52 0.015
Intro-abdominal drainage time (d) 4.2 ± 1.6 4.6 ± 1.8 0.176
Incision infection (%) 12 (8/68) 9 (6/66) 0.779
Central lines infection (%) 9 (6/68) 11 (7/66) 0.777
Pneumonia infection (%) 12 (8/68) 9 (6/66) 0.097
Urinary infection (%) 13 (9/68) 2 (1/66) 0.017
First defecation time (d) 3.6 ± 1.8 2.8 ± 1.6 0.007
Diarrhea incidence (%) 46 (31/68) 24 (16/66) 0.012
Urinary catheters time (d) 7.1 ± 2.6 6.6 ± 2.8 0.286
Abdominal cramping (%) 49 (33/68) 23 (15/66) 0.017
Abdominal distension (%) 51 (35/68) 33 (22/66) 0.038
Intake time of fluid diet (d) 3.6 ± 1.2 3.2 ± 1.8 0.131
Intake time of solid diet (d) 5.2 ± 1.6 4.9 ± 1.6 0.280
Side effects of probiotic use 0 0 N/A
Duration of postoperative pyrexia (>38.5°C) (d) 6.98 ± 2.22 6.02 ± 1.68 0.006
Hypoalbuminemia (%) 47 (32/68) 27 (18/66) 0.021
Cumulative duration of antibiotic therapy 7.56 ± 2.26 6.22 ± 1.96 <0.001
Postoperative hospital stay 12.96 ± 3.06 11.26 ± 2.52 <0.001
Hospital charge (Yuan) 58262.36 ± 10262.36 52261.16 ± 12168.28 0.002
Death case 0 0 N/A
Serum zonulin (ng/mg protein) 1.36 ± 0.50 0.42 ± 0.36 <0.001
ALT, alanine transarninase (normal value, 0–40 U/L); AST, aspartate aminotransferase (normal value, 0–40 U/L).
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18.16 vs 36.28 ± 18.92, P < 0.001; AST, control vs PRO,
45.62 ± 22.68 vs 36.18 ± 21.52, P = 0.015, Table 2). The
gastrointestinal recover quicker in the PRO group for
PRO group got shorter first defecation time (control vs
PRO, 3.6 ± 1.8 vs 2.8 ± 1.6, P = 0.007), less abdominal
cramping (control vs PRO, 49% vs 23%, P = 0.017), and
abdominal distension (control vs PRO, 51% vs 33%, P =
0.038).
PRO reduce the postoperative serum zonulin
concentration
The serum zonulin was not significantly different between
the two groups (0.30 ± 0.62 ng/mg protein vs. 0.36 ±
0.38 ng/mg protein, P = 0.502) perioperately. The serum
zonulin concentration in the control group (1.36 ±
0.50 ng/mg protein) was significantly higher than in the
PRO group (0.42 ± 0.36 ng/mg protein, P < 0.001, Table 2)
after 10 d postoperative treatment. Results indicated that
PRO lower the postoperative zonulin level efficiently after
CLM surgery. Ccompared with the results in our pervious
study, which indicated that PRO could reduce the zonulinlevel after CRC surgery without liver metastases, the post-
operative zonulin level of the control group was higher in
our present study of CRC with liver metastases (CLM),
compared with that without liver metastases (1.36 ±
0.50 ng/mg protein vs 1.08 ± 0.28 ng/mg protein). And
postoperative septicemia incidence in the control group
was also higher in our present study (88% vs 73%, P =
0.034). Therefore, we hypothesized that another barrier
also played a role in the change of postoperative zonulin
level inCLM, such as liver barrier. We plan to investigate
the effects of PRO on the liver barrier.
We use the intestinal permeability to exclude patients
with intestinal barrier dysfunction. Only patients with nor-
mal intestinal permeability at day 3 postoperatively, were
included in the following analysis to eliminate the intestinal
interference (Table 3 & Additional file 3: Table S3). We use
the serum zonulin level before treatment to estimate the
normal interval zonulin level. Intestinal permeability was
assessed using the L/M test to distinguish the normal level
of intestinal permeability from higher level at postoperative
day 3. The average L/M ratio (including the ratio of control
and PRO groups) before treatment was 0.161 ± 0.059, with
Table 3 Comparison of serum zonulin with the postoperative infectious complications between probiotics and control
the patients with normal intestinal barrier function (Intention-to-treat)
Outcomes Intention-to-treat
Control (n = 30) PRO (n = 30) P Value
Serum zonulin (ng/mg protein) 0.72 ± 0.26 0.51 ± 0.29 0.004
Septicemia (%)
Total 87 (26/30) 50 (15/30) 0.005
HZ 95 (19/20) 66 (10/15) 0.064
LZ 70 (7/10) 33 (5/15) 0.111
HZ vs. LZ HZ vs LZ (83% vs 48%), P = 0.006
Correlation between septicemia and zonulin, r = 0.613, P < 0.001
Urinary infection (%)
Total 20 (6/30) 0 (0/30) 0.024
HZ 15 (3/20) 0 (0/15) 0.244
LZ 30 (3/10) 0 (0/15) 0.052
HZ vs. LZ HZ vs LZ (9% vs 12%), P = 0.686
Diarrhea incidence (%)
Total 60 (18/30) 27 (8/30) 0.018
HZ 50 (10/20) 27 (4/15) 0.296
LZ 80 (8/10) 27 (4/15) 0.015
HZ vs. LZ HZ vs LZ (40% vs 48%), P = 0.603
Duration of postoperative pyrexia (>38.5°C) (d)
Total 6.99 ± 2.38 5.49 ± 3.21 0.044
HZ 7.97 ± 1.77 (n = 20) 8.02 ± 0.87 (n = 15) 0.927
LZ 5.01 ± 2.27 (n = 10) 2.95 ± 2.61 (n = 15) 0.054
HZ vs. LZ HZ vs LZ (7.99 ± 1.43 vs 3.78 ± 2.64), P < 0.001
Cumulative duration of antibiotic therapy (d)
Total 7.17 ± 1.60 6.13 ± 1.72 0.019
HZ 7.90 ± 1.21 (n = 20) 7.47 ± 1.19 (n = 15) 0.298
LZ 5.70 ± 1.25 (n = 10) 4.80 ± 0.94 (n = 15) 0.052
HZ vs. LZ HZ vs LZ (7.71 ± 1.20 vs 5.16 ± 1.14), P < 0.001
Postoperative hospital stay
Total 12.87 ± 3.01 11.33 ± 2.22 0.029
HZ 14.15 ± 2.64 (n = 20) 13.13 ± 1.60 (n = 15) 0.197
LZ 10.30 ± 1.89 (n = 10) 9.53 ± 0.83 (n = 15) 0.177
HZ vs. LZ HZ vs LZ (13.71 ± 2.28 vs 9.84 ± 1.38), P < 0.001
Hospital charge (Yuan) 60196.12 ± 6532.16 53628.22 ± 6513.28 <0.001
HZ, high serum zonulin (≥0.6 ng/mg protein); LZ, low serum zonulin (<0.6 ng/mg protein); total = HZ + LZ; NS, No significance.
Numerical data between groups were compared by the t-test and nominal data by Pearson χ2 test or Fisher’s exact test.
HZ vs LZ compares these subgroups without regard to treatment.
There was also a significant correlation between zonulin and duration of postoperative pyrexia (r = 0.919, p < 0.001), cumulative duration of antibiotic therapy and
zonulin (r = 0.936, p < 0.001), and postoperative hospital stay (r = 0.911, p < 0.001).
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only analyze the patients with the L/M ratio less than 0.171,
which were confirmed 3 d after CLM surgery. Further ana-
lysis also indicated that there was no significant difference
between the control and PRO groups before treatment
(0.156 ± 0.062 vs 0.167 ± 0.056, P = 0.287).PRO lowered postoperative infection related
complications in patients with normal intestinal barrier
function
The baseline characteristics of patients with normal in-
testinal barrier function were re-evaluated. There was no
significant difference about the baseline characteristics
Figure 2 Probiotics lowered the postoperative bacterial
translocation and endotoxin (Intention-to-treat analysis). PRO
effectively decreased the plasma concentration of endotoxin in
patients of colorectal liver metastases with normal postoperative
intestinal barrier function, compared with the control group (n = 30
for control group and n = 30 for PRO group). Black bar represents
the control group, and gray bar represents the PRO group. *
(Control) vs. Preoperative, P < 0.05; # (PRO) vs. Preoperative, P < 0.05;
* vs. #, P < 0.05. Numerical data are expressed as the means ±
standard deviation, and compared by the t-test between groups.
Plasma endotoxin was determined preoperatively (hospital admission
day), and postoperatively (10 d treatment after surgery).
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Table S4). The postoperative infection-related parame-
ters showed significant difference in Table 3 of
intention-to-treat groups were selected for further ana-
lysis. For the analysis of patients with normal intestinal
barrier function, serum zonulin level was not signifi-
cantly different before treatment (0.32 ± 0.60 ng/mg
protein vs. 0.36 ± 0.39 ng/mg protein, P = 0.761); while
the serum zonulin concentration after 10 d postopera-
tive treatment in the control group was significantly
higher than in the PRO group (0.72 ± 0.26 ng/mg pro-
tein vs. 0.51 ± 0.29 ng/mg protein, P = 0.004, Table 3).
The incidence of postoperative septicemia was 87% (26/
30) in the control and 50% (15/30) in the PRO group
(P = 0.005). Further analysis found that the incidence of
postoperative septicemia with high serum zonulin levels
did not differ between the two groups (95 (19/20) vs.
66 (10/15), P =0.064). . When patients were grouped
according to serum zonulin level, the incidence of post-
operative septicemia in the high serum zonulin group
was significantly higher than that in the low serum
zonulin group (83% (29/35) vs. 48% (12/25), P =0.006,
Table 3). Similar results were indicated in the per-
protocol analysis (Additional file 3: Table S3). The dur-
ation of postoperative pyrexia, the cumulative duration
of antibiotic therapy and postoperative hospital stay all
showed similar results to those of septicemia. The de-
tailed comparison between the two groups is shown in
Table 3 for the intention-to-treat analysis and
Additional file 3: Table S3 for per-protocol analysis.
Furthermore, Spearman’s correlation was used to assess
the relationship between zonulin level and outcome.PRO got the effective descend on concentration of
plasma endotoxin
Patients with normal intestinal barrier function were
further analyzed. Before treatment, the plasma con-
centrations of endotoxin indicated no significant dif-
ference (3.32 ± 0.68 in the control group vs. 3.26 ±
0.82 in the PRO group, P = 0.759). Control group
showed a higher level of plasma endotoxin after 10
d postoperative treatment (3.96 ± 1.12 vs. 3.32 ± 0.68,
P = 0.015), while PRO group showed a lower level of
plasma endotoxin after treatment (2.80 ± 0.88 vs.
3.26 ± 0.82, P = 0.041). When the two groups were
compared postoperatively, the PRO group was indi-
cated significantly lower level of plasma endotoxin
(3.96 ± 1.12 in the control group vs. 2.80 ± 0.88 in
the PRO group, P < 0.001), compared with control
group (Figure 2 & Additional file 5: Figure S1).
Spearman’s correlation indicated that there was a
direct correlation between the postoperative serum
zonulin level and the plasma endotoxin (r = 0.962).PRO reduced postoperative infection rate and positive
rate of the blood microbial DNA
To determine the types of infectious bacteria and positive
rate of microbial culture, bacterial DNA levels in the
blood, central line tips and sputum sample cultures were
investigated. During the postoperative 72 h period, the
growth rate of positive bacterial cultures (including blood,
central lines and sputum) in the control group (53%, 16 in
30 patients) was significantly higher than the PRO group
(23%, 7 in 30 patients), as shown in Table 3 (P =0.033).
The positive rate of bacteria in the control group (30%, 9
in 30 patients) was also found significantly higher com-
pared with the PRO group (7%, 2 in 30 patients, P = 0.042,
Table 4 & Additional file 6: Table S5). Microbial DNA was
found in all patients whose blood cultures were positive.
The overall blood bacterial DNA positive rate in the con-
trol group (53%, 16/30) was significantly higher than in
the PRO group (20%, 6/30, P = 0.015). Only 3 pathogens
were detected in the blood samples, Escherichia coli,
Staphylococcus aureus and Aeruginosin; Escherichia coli
was the most common identified bacteria in 47.83% (11/
23) of samples with bacteria.
PRO inhibit the p38 MAPK signaling pathway
It is reported that the p38 MAPK signaling pathway is
involved in the protection of intestinal barrier function
Table 4 Culture of bacterial culture of blood, central lines and sputum (Intention-to-treat)
Sample Control group (n = 30) PRO group (n = 30)
Bacterium Blood Central lines sputum Blood Central lines sputum
Escherichia coli 6 1 2 1 0 1
Staphylococcus aureus 2 1 2 1 1 1
Klebsiella pneumoniae 0 0 1 0 0 1
Aeruginosin 1 0 0 0 1 0
Bacterial positive patient 9 2 5 2 2 3
Total 16 7
The total bacterial positive rate in control group was 53.33% (16 in 30 patients); in PRO group 23.33% (7 in 30 patients), P = 0.033; bacterial positive rate of the
blood in the control group was 30.00% (9 in 30 patients), while in PRO group was 6.67% (2 in 30 patients), P = 0.042.
Nominal data by Pearson χ2 test or Fisher’s exact test between groups.
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between p38 MAPK signaling pathway and the liver bar-
rier function. To determine whether the PRO treatment
was associated with the induction of p38 MAPK signal-
ing pathway or not, samples from adjacent normal liver
tissues (>1 cm form the metastatic tumor) were obtained
from CLM patients (n = 5 for each group). The results
showed that the expression of p38 MAPK was lower in
the PRO group (1.26 ± 0.60), compared with the control
group (2.28 ± 0.68, P = 0.033).
Randomized clinical trials regarding the effects of peri-
operative PRO treatment on the outcomes of colorectal
cancer were rare, especially for CLM. Our pervious
study indicated the perioperative use of PRO to protect
human intestinal barrier function and prevent postoper-
ative infectious complications after CRC surgery [1,11].
No study has reported the effects of pre and postopera-
tive use of PRO on the liver barrier after CLM surgery.
Here, we first investigated the relation between probio-
tics and the liver barrier clinically.
In our study, a double-center and double-blind random-
ized clinical trial was performed. Zonulin is a newly identi-
fied protein biomarker of barrier function [22,25,28].
Interestingly, we found the postoperative zonulin level
(1.36 ± 0.50 ng/mg protein) of the control group was
higher in CRC with liver metastases compared with that
without liver metastases (1.08 ± 0.28 ng/mg protein) [1].
So we hypothesize liver barrier also contributed to the
change of postoperative zonulin level in CLM. Results
showed that PRO could efficiently lower the postoperative
infection related complications in CLM patients with nor-
mal intestinal barrier function, which indicated that liver
barrier dysfunction also contributed to the postoperative
infection related complications of CLM patients. A novel
concept of the “clinical regulatory pathway” (CP) was
proposed [1], which was described as the mechanism
by which a clinical treatment cause a series of se-
quenced molecular and clinical responses and just
looks like the molecular signal transduction pathway.
CP could link molecular signals and clinical outcomesmore intuitively and vividly. So we drew a CP picture
to elucidate the relation about PRO, liver barrier, in-
testinal barrier and postoperative infection related
complications (Figure 3). We also promote the CP of
the protective effects of PRO against postoperative in-
fection related complications through the liver barrier
in CLM patients: peri-operative administration of
PRO might inhibit the p38 MAPK signaling pathway,
which will extend the understanding of zonulin about
its regulation on the barrier function after surgery
[29-33].
Firstly, the serum zonulin level was not significantly
different between the control and PRO groups, which
was higher in the PRO group after 10 d postoperative
treatment (Table 2). The incidence of postoperative
septicemia was higher (87%, 26/30) in the control group
compared with 50% (15/30) in the PRO group. However,
either the septicemia rate was not shown significant dif-
ference between the two groups, while postoperative
septicemia rate was significantly higher in the high
serum zonulin group than the low serum zonulin group
indicated septicemia may be regulated by the organ bar-
rier. It shown that incidence of postoperative septicemia
was correlated with the serum zonulin level (r = 0.613
for or the intention-to-treat analysis and r = 0.647 for
per-protocol analysis). Therefore, we can deduce that
PRO could efficiently reduce the zonulin level and then
lower the incidence of postoperative septicemia (PRO→
zonulin→ septicemia).
Furthermore, duration of postoperative pyrexia, cumu-
lative duration of antibiotic therapy and postoperative
hospital stay were also suggesting the regulation by
zonulin. Combined with the, we can deduce that:
PRO→ zonulin→ septicemia→ duration of postopera-
tive pyrexia time→ duration of antibiotic therapy→
postoperative hospital stay→ hospital charge.
The finding that Escherichia coli was the main bacteria
identified in blood samples (Table 3) indicated that
pathogen translocated from the intestinal tract to the
blood through the liver barrier is the most important
Figure 3 Schematic diagram for the clinical regulatory pathway of probiotics.
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intestinal barrier dysfunction [1,11]. We deduce that
perioperative use of PRO may reduce postoperative
zonulin levels, injure the liver barrier and so on. (PRO→
zonulin→ liver barrier→ septicemia→ duration of
postoperative pyrexia time→ duration of antibiotic ther-
apy→ postoperative hospital stay→ hospital charge).
Combined with the overall liver function indexes
(Table 2), both ALT and AST were significantly lowered
by the treatment of PRO, indicating the protection of
PRO on liver function, which may contribute to theinjury of liver function [34]. Liver function can be added
to the CP pathway: PRO→ zonulin→ liver function→
liver barrier→ septicemia→ duration of postoperative
pyrexia time→ duration of antibiotic therapy→ postop-
erative hospital stay→ hospital charge.
Investigation of the plasma endotoxin indicated no sig-
nificant difference before treatment (P = 0.759). Control
group showed a higher level, whereas PRO group
showed a lower level of plasma endotoxin after 10 d
postoperative treatment, which showed a significant
difference. Spearman’s correlation indicated a direct
Liu et al. BMC Gastroenterology  (2015) 15:34 Page 11 of 13correlation between the postoperative serum zonulin
level and the plasma endotoxin (r = 0.962). As is well-
known that septicemia can be caused by endotoxin
[35], we further improve our CP pathway as: PRO→
zonulin→ liver function→ liver barrier→ endotoxin→
septicemia→ duration of postoperative pyrexia time→
duration of antibiotic therapy→ postoperative hospital
stay→ hospital charge.
P38 MAPK, a Ser/Thr kinase belonging to the family
of MAPKs, was selected as the signal molecular in the
regulation of zonlulin, which is related to the expression
level of several inflammatory genes, while inhibition of
p38 MAPK phosphorylation by PRO could protect intes-
tinal barrier from dysfunction [27]. Our prevoious study
also showed that PRO could inhibit the expression of
p38 MAPK, lower the clinical effects of zonulin and de-
crease the intestinal permeability [1]. Accordingly, we
hypothesize that the effects of PRO were mediated via
the p38 MAPK pathway and then play its role in the
liver barrier. Results verified that the expression level of
p38 MAPK was lower in the PRO group compared with
the control group (P = 0.033). Above all, our CP of PRO
on postoperative septicemia in colorectal cancer surgery
can be presented as: PRO→ p38 MAPK→ zonulin→
liver function→ liver barrier→ endotoxin→ septicemia→
duration of postoperative pyrexia time→ duration of anti-
biotic therapy→ postoperative hospital stay→ hospital
charge. Combined with the CP that PRO regulate intes-
tinal barrier, we deduce that PRO regulate postoperative
infection related complications in patients of CLM via two
pathway—intestinal barrier and liver barrier (Figure 3).
It is reported that for severe acute pancreatitis pa-
tients, prophylactic use of PRO could not only fail to re-
duce the risk of occurrence of infectious complications,
but, on the contrary, increase the patients’ mortality due
to the high oxygen demand and the severe gastrointes-
tinal ischemia [36]. While in our study, no death case
was reported, which may because the intestinal barrier
and liver barrier was not injured so seriously. One of the
advantages is that although our study is a double→ cen-
tered one, the interference of different operators to the
study results was not the most important [37].
We only pointed out one of the possible signal trans-
duction pathways about the zonulin expression regulated
by PRO [38]. It is quite reasonable that zonulin may in
turn have a regulation on p38 MAPK pathway or a
double regulation between P38 MAPK and zonulin, given
similar signaling of the zonulin prokariotic analogue Zot
[39],further basic studies may be needed Assessment of
numerous outcome gives rise to a multiple comparison
issue, especially marginally significant results, which re-
quire cautious analyse. Fortunately, the consistency of
findings lends support to the effectiveness of treatment
with PRO [11]. Comparison of HZ and LZ subsetssuffered from small sample size and not randomized com-
parison issues and the randomization protection also does
not apply.
Conclusion
To sum up, perioperative PRO treatment could reduce
the rate of postoperative septicemia and maintain the
liver barrier in patients undergoing CLM surgery, which
is associated with reduced serum zonulin level. We
propose a new model about the regulation of PRO to
liver barrier via CP (Figure 3). Serum zonulin levels
could be an early biomarker for septicemia. We recom-
mend the preoperative oral intake of PRO combined
with postoperative PRO treatment in patients who
underwent CLM surgery.
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translocation and endotoxin (Per-protocol analysis). PRO effectively
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